Creator of Herceptin goes Hollywood in TV biopic

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

Only in Hollywood can New Orleans stand in for Los Angeles while a suave crooner portrays a serious scientist.

Only in Hollywood can New Orleans stand in for Los Angeles while a suave crooner portrays a serious scientist.

In the upcoming film “Living Proof,” Dennis Slamon, MD, PhD, will be played by Harry Connick, Jr

. Dr. Slamon, of course, is the driving force behind the development of trastuzumab (Herceptin); Connick is best known for his Southern charm as a singer and actor.

“Living Proof,” will air in October on the Lifetime TV network. The movie is based on the 1998 book HER-2: The Making of Herceptin, by Robert Bazell, a medical correspondent for NBC. According to Connick’s website, the actor conveys Dr. Slamon’s “relentless battle to keep the drug trials afloat and save the lives of thousands of women.”

The movie was executive produced by Renee Zellweger, whose publicist, Nanci Ryder, was a patient of Dr. Slamon. Angie Harmon portrays philanthropist Lily Tartikoff, who helped fund the Herceptin research.

The movie was shot in New Orleans at the behest of Mr. Connick, who has spearheaded post-Hurricane Katrina efforts to revive his hometown.

“Living Proof” will be the centerpiece of Lifetime’s annual public awareness campaign, “Stop Breast Cancer for Life.”

Dr. Slamon, who continues to serve as chief of the Oncology Treatment Center at UCLA, seems to be keeping mum on the deal. Aside from some praise for Bazell’s book (“It’s very good”), he had one comment for ONI: “I don’t know why anyone would want to make a movie about me!”

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content